Results 71 to 80 of about 195,174 (257)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS, ANGIOTENSIN II RECEPTOR ANTAGONISTS AND RENOPROTECTION

open access: yesTurkish Journal of Nephrology, 2019
-
Alpaslan ERSOY, Kamil DİLEK
doaj  

The use of angiotensin-converting enzyme inhibitors in general medicine

open access: yesSouth African Family Practice, 2012
Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs commonly used in the management of hypertension, congestive heart failure, cerebrovascular disease, stable coronary heart disease and diabetes-associated nephropathy.
M.L.I. Mashitisho
doaj   +1 more source

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 879-887, April 2025.
Abstract Background Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF). Aims This study aimed to characterize patients with exertional dyspnoea and normal/near‐to‐normal N‐terminal pro‐brain natriuretic peptide (NT ...
Emmanuelle Berthelot   +8 more
wiley   +1 more source

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki   +11 more
wiley   +1 more source

Lung Diseases and Angiotensin-Converting Enzyme

open access: yesEurasian Journal of Medicine, 2019
-
Mecit Süerdem
doaj  

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

The Effect of Eight-Week Aerobic Training on Serum Angiotensin Converting Enzyme and Lipid Profile in Inactive Overweight Women [PDF]

open access: yesJournal of Advanced Biomedical Sciences, 2019
Background & Objective: At present, the prevalence of hypertension is growing and one of the contributing factors in the occurrence and development of hypertension and atherosclerosis is impaired renin–angiotensin system which in this system endothelium ...
nahid Bijeh   +4 more
doaj  

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

Angiotensin converting enzyme

open access: yes
Angiotensin Converting Enzyme (ACE), is a zinc containing metallopeptidase, best known for its role in the conversion of Ang I in the active peptide Ang II, which plays a pivotal role in the blood pressure (BP) regulation trough the Renin Angiotensin System (RAS). In the last decades RAS has been deeply studied in all its aspects and implications.
Arrighi, F., Berrino, E., Secci, D.
  +5 more sources

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy